A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Do Early Phase Oncology Trials Predict Clinical Efficacy in Subsequent Biomarker-Enriched Phase III Randomized Trials?
TL;DR: Overall, in early phase trials, ORR has minimal bias and median PFS appears to be slightly overestimated, which suggests early phase trial results may be inconsistent with subsequent RCT.
Journal ArticleDOI
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
Giuseppe Curigliano,B. Shapiro,Rebecca Kristeleit,Albiruni Ryan Abdul Razak,Stephen Leong,Maria Alsina,Antonio Giordano,Karen A. Gelmon,Erica Stringer-Reasor,Ulka N. Vaishampayan,M M Middleton,Anthony J. Olszanski,Hope S. Rugo,Kenneth A. Kern,Nuzhat Pathan,Rachelle Perea,Kristen J. Pierce,Sarah C. Mutka,O. Wainberg +18 more
Journal ArticleDOI
Abstract CT168: Randomized phase 2 trial of sunitinib or cediranib in alveolar soft part sarcoma
Naoko Takebe,James Q. Nguyen,Shivaani Kummar,Albiruni Ryan Abdul Razak,Sant P. Chawla,Suzanne George,Shreyaskumar Patel,Mary Louise Keohan,Sujana Movva,Geraldine C O’Sullivan,Khanh T. Do,Larry D. Anderson,Lamin Juwara,Brooke Augustine,Seth A. Steinberg,Laura Kuhlmann,S. Percy Ivy,James H. Doroshow,Alice P. Chen +18 more
TL;DR: The study did not meet its endpoints for ORR, progression-free survival (mPFS), and PFS rate at 24 weeks for the 2 arms (C and S) were evaluated; T and N cohorts were assessed separately in each arm.
Journal ArticleDOI
The impact of surgical resection margins on outcomes for adults with head and neck osteosarcomas: A Canadian sarcoma research and Clinical Collaboration (CanSaRCC) study.
Sharon Tzelnick,Hagit Peretz Soroka,Najifah Tasnim,Ralph W. Gilbert,Jonathan C. Irish,David Goldstein,Patrick J. Gullane,Douglas B. Chepeha,Christopher Mkl Yao,Axel Sahovaler,Ian J. Witterick,Eric Monteiro,Joel Davies,Brian O'Sullivan,Ezra Hahn,Ali Hosni,Albiruni Ryan Abdul Razak,John R. de Almeida +17 more
Journal ArticleDOI
1664MO Tumor-naïve methylomes and fragmentomes during pembrolizumab (P) in metastatic cancer patients
E. Zhao,E. Sanz García,Z. Liu,Kayla Marsh,Albiruni Ryan Abdul Razak,Anna Spreafico,Philippe L. Bedard,Aaron R. Hansen,Stephanie Lheureux,Dax Torti,Bao H. Lam,Tevor Pugh,Lillian L. Siu +12 more
TL;DR: In this paper , the authors report the first joint analysis of tumour-naïve cell-free methylomes and fragmentomes in a P-treated cohort and show that cancer-specific methylation (CSM) and higher short fragment fraction (SFF) are associated with favorable response.